These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35163005)

  • 1. Pan-Cancer Prediction of Cell-Line Drug Sensitivity Using Network-Based Methods.
    Pouryahya M; Oh JH; Mathews JC; Belkhatir Z; Moosmüller C; Deasy JO; Tannenbaum AR
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer network activity associated with therapeutic response and synergism.
    Serra-Musach J; Mateo F; Capdevila-Busquets E; de Garibay GR; Zhang X; Guha R; Thomas CJ; Grueso J; Villanueva A; Jaeger S; Heyn H; Vizoso M; Pérez H; Cordero A; Gonzalez-Suarez E; Esteller M; Moreno-Bueno G; Tjärnberg A; Lázaro C; Serra V; Arribas J; Benson M; Gustafsson M; Ferrer M; Aloy P; Pujana MÀ
    Genome Med; 2016 Aug; 8(1):88. PubMed ID: 27553366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    Huang S; Hu P; Lakowski TM
    BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modular within and between score for drug response prediction in cancer cell lines.
    Wang S; Li J
    Mol Omics; 2020 Feb; 16(1):31-38. PubMed ID: 31802092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving prediction of phenotypic drug response on cancer cell lines using deep convolutional network.
    Liu P; Li H; Li S; Leung KS
    BMC Bioinformatics; 2019 Jul; 20(1):408. PubMed ID: 31357929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
    Wang L; Li X; Zhang L; Gao Q
    BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
    Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
    Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic analysis of genotype-specific drug responses in cancer.
    Kim N; He N; Kim C; Zhang F; Lu Y; Yu Q; Stemke-Hale K; Greshock J; Wooster R; Yoon S; Mills GB
    Int J Cancer; 2012 Nov; 131(10):2456-64. PubMed ID: 22422301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
    Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
    Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of anticancer drug sensitivity using an interpretable model guided by deep learning.
    Pang W; Chen M; Qin Y
    BMC Bioinformatics; 2024 May; 25(1):182. PubMed ID: 38724920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
    Weigelt B; Warne PH; Downward J
    Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical drug response prediction from preclinical cancer cell lines by logistic matrix factorization approach.
    Emdadi A; Eslahchi C
    J Bioinform Comput Biol; 2022 Apr; 20(2):2150035. PubMed ID: 34923927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting cancer drug response using parallel heterogeneous graph convolutional networks with neighborhood interactions.
    Peng W; Liu H; Dai W; Yu N; Wang J
    Bioinformatics; 2022 Sep; 38(19):4546-4553. PubMed ID: 35997568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
    Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel heterogeneous network-based method for drug response prediction in cancer cell lines.
    Zhang F; Wang M; Xi J; Yang J; Li A
    Sci Rep; 2018 Feb; 8(1):3355. PubMed ID: 29463808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting Drug Response Based on Multi-Omics Fusion and Graph Convolution.
    Peng W; Chen T; Dai W
    IEEE J Biomed Health Inform; 2022 Mar; 26(3):1384-1393. PubMed ID: 34347616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal Cancer Cell Line Proteomes Are Representative of Primary Tumors and Predict Drug Sensitivity.
    Wang J; Mouradov D; Wang X; Jorissen RN; Chambers MC; Zimmerman LJ; Vasaikar S; Love CG; Li S; Lowes K; Leuchowius KJ; Jousset H; Weinstock J; Yau C; Mariadason J; Shi Z; Ban Y; Chen X; Coffey RJC; Slebos RJC; Burgess AW; Liebler DC; Zhang B; Sieber OM
    Gastroenterology; 2017 Oct; 153(4):1082-1095. PubMed ID: 28625833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.
    Uitdehaag JC; de Roos JA; Prinsen MB; Willemsen-Seegers N; de Vetter JR; Dylus J; van Doornmalen AM; Kooijman J; Sawa M; van Gerwen SJ; de Man J; Buijsman RC; Zaman GJ
    Mol Cancer Ther; 2016 Dec; 15(12):3097-3109. PubMed ID: 27587489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.